CSIMarket
 
Xeris Biopharma Holdings Inc   (NASDAQ: XERS)
Other Ticker:  
 
 
Price: $3.5500 $-0.07 -1.934%
Day's High: $3.64 Week Perf: -1.11 %
Day's Low: $ 3.52 30 Day Perf: 5.97 %
Volume (M): 1,328 52 Wk High: $ 3.87
Volume (M$): $ 4,715 52 Wk Avg: $2.69
Open: $3.62 52 Wk Low: $1.69



 Market Capitalization (Millions $) 529
 Shares Outstanding (Millions) 149
 Employees 72
 Revenues (TTM) (Millions $) 187
 Net Income (TTM) (Millions $) 36
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc. is a US-based pharmaceutical company focused on developing and commercializing innovative, differentiated therapeutics for people with serious and life-threatening conditions. Xeris was founded in 2005 and is headquartered in Chicago, Illinois.

The company's primary focus is on the development of injectable and infusible drug formulations that are stable at room temperature, making them more convenient and accessible for patients. Their lead product, Gvoke HypoPen, is a ready-to-use, premixed, pre-measured glucagon emergency kit that treats severe hypoglycemia in adults and children with diabetes. The kit received FDA approval in August 2019 and is available for purchase in the US.

Xeris has also developed several other products under development, including a ready-to-use glucagon rescue pen for hypoglycemia associated with insulin therapy, a stable liquid glucagon for use in a healthcare setting, and an epilepsy treatment using Xeris' proprietary formulation technology.

In addition to its internal development programs, Xeris has entered into strategic partnerships and collaborations to further advance their technology and product pipeline. These partnerships include collaborations with Zealand Pharma, Intarcia Therapeutics, and Vizient, among others.

Xeris is led by a highly experienced executive team and has raised over $100 million in funding, including a successful initial public offering in 2018. The company has also been recognized for its innovation and leadership in the industry, receiving awards such as the Red Herring Top 100 North America and being named as one of FierceBiotech's Fierce 15 in 2018.

Overall, Xeris Biopharma Holdings Inc. is a rapidly growing and innovative pharmaceutical company with a strong focus on developing therapeutics that improve patient outcomes and make treatments more accessible and convenient for patients.


   Company Address: 1375 West Fulton Street Chicago 60607 IL
   Company Phone Number: 445-5704   Stock Exchange / Ticker: NASDAQ XERS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -4.03%    
BHC   -11.4%    
MNK   -39.2%    
SRPT   -1.75%    
TEVA   -3%    
VTRS   -2.81%    
• View Complete Report
   



Business Update

Xeris Biopharma Holdings Pioneering Advancements and Engaging the Investment Community

Published Thu, Aug 22 2024 11:47 AM UTC

Abstract: Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a forefront player in the biopharmaceutical sector, continues to demonstrate its commitment to enhancing patient lives through the development and commercialization of innovative therapies. As part of its strategic initiatives, the company will actively engage the investment community by participating in significant up...

Business Update

Ignition of Innovation Xeris Biopharmas Strategic Inducement Grants Fuel Future Growth

Published Wed, Jul 3 2024 6:47 PM UTC

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a dynamic biopharmaceutical company dedicated to enhancing patient lives through the development and commercialization of groundbreaking therapies, has recently made a significant announcement that underlines its commitment to attracting top talent and fostering innovation. On July 1, 2024, Xeris revealed that the Compensation C...

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc. Reports Increase in Revenue but Fails to Achieve Profitability in Q1 2024

Xeris Biopharma Holdings Inc, a growth-oriented biopharmaceutical company based in Chicago, recently announced its financial results for the first quarter of 2024. The company reported a surge in revenue by 22.418% to $40.64 million compared to the same reporting period the previous year. However, despite this positive revenue growth, Xeris Biopharma also experienced an increased deficit per share at $-0.14, up from $-0.10 per share in the previous period.
In the Major Pharmaceutical Preparations sector, Xeris Biopharma's revenue growth in the first quarter of 2024 aligns with its peers, who saw an average business growth of 2.72% during the same period. This highlights the company's ability to perform well within its industry.

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc Faces Intensified Losses in Fiscal Report Ending December 31, 2023

Xeris Biopharma Holdings Inc, a major pharmaceutical preparations company, recently released its financial results for the October to December 31, 2023 time-frame. Despite a decrease in the company's earnings per share, there was a significant surge in revenue, indicating positive growth for the company.
The company reported a shortfall per share of $-0.10 during the specified time-frame, compared to a shortfall of $-0.09 in the previous reporting period. Although this represents a slight increase in loss per share, it is important to note that there was substantial revenue growth during the same period. Xeris Biopharma's revenue increased by an impressive 33.931% to $44.39 million, up from $48.32 million in the previous reporting period.







Xeris Biopharma Holdings Inc's Segments
Product revenue net    97.41 % of total Revenue
Gvoke    42.28 % of total Revenue
Recorlev    22.47 % of total Revenue
Keveyis    32.66 % of total Revenue
Royalty contract and other revenue    2.59 % of total Revenue

  Xeris Biopharma Holdings Inc Outlook

On May 9 2024 the Xeris Biopharma Holdings Inc provided following guidance

Xeris Biopharma Holdings Inc. reported its financial results for the first quarter of 2024, showing a 25% growth in total product revenue compared to the same period last year. This growth was achieved despite facing challenges such as an estimated $3 million negative impact on Gvoke revenue due to the Change Health.

The company remains committed to improving patient lives through the development and commercialization of innovative products across various therapies. Xeris Biopharma continues to focus on its growth-oriented approach to biopharmaceuticals.

In addition to the financial results, Xeris Biopharma also highlighted recent events in the first quarter of 2024. The company is dedicated to...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com